Annexin appoints Dr. Mario Fsadni as Head of Ophthalmology
Annexin Pharmaceuticals AB (publ) announces that Dr Mario Fsadni, an ophthalmologist with extensive global experience from leading novel compounds through clinical development into marketed drugs, will join as a new team member and Therapy Area Head, Ophthalmology.
STOCKHOLM (29 March, 2022) - Dr. Fsadni, MBChB, MRC Ophth, MSc, LLM, FMH has obtained his Medical Degree and Ophthalmology training in Manchester, UK. He was previously the Global Medical Director at Novartis Ophthalmics and Director Product Development in Ophthalmology at Allergan, before starting a consultancy designed specifically for the development of pharmaceutical products for ophthalmic disorders. He has had an active role in projects spanning all sub-therapeutic areas in ophthalmology, 16 of which have had successful global marketing approval.
“Annexin Pharmaceuticals is in a key growth phase entering clinical studies in retinal vein occlusion (RVO) planned to start in the USA this year, so we are welcoming Dr. Fsadni as a formal member of our team. He has led multiple clinical programs in ophthalmology to global marketing approvals within mid-size and large pharmaceutical. Dr Fsadni has already contributed to our Phase 2 study design in RVO as a consultant and will bring additional leadership and valuable insights to our program both as a clinician and an experienced drug developer” says Anna Frostegård, MD, PhD, Chief Scientific and Medical Officer.
“The current therapies targeting complications of RVO are far from satisfactory. The novel mechanisms of action of ANXV addresses an important medical need and may lead to better vision in patients with retinal vein occlusions and other retinal diseases. I am excited by this opportunity to join the Annexin Pharmaceutical’s team and continue the development of ANXV, potentially shifting the treatment paradigm for a common cause of serious vision loss” says Dr. Fsadni.
Dr. Fsadni is based in the U.K. and assumes his new position immediately.
About Annexin Pharmaceuticals AB (publ)
Annexin Pharmaceuticals AB is a world-leading biotechnology company in the Annexin A5 field for the treatment of various vascular diseases. The company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for short term treatment of patients with injuries and inflammation of the blood vessels. The company has an extensive patent portfolio for the treatment of diseases that occur due to the damage and inflammation of the blood vessels. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of ANXV.
The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company´s Certified Adviser, email certifiedadviser@redeye.se or phone +46 8 121 576 90.
For further information please visit www.annexinpharma.com or contact:
CEO Anders Haegerstrand at +46 707 575 50 37.
The information was submitted for publication at 15.00 CEST on 29 March 2022
Tags: